4E Therapeutics

4E Therapeutics is an Austin, TX based company dedicated to developing innovative medications for neuropathic pain. The scientific foundation of the company is centered on the idea that neuropathic pain can be effectively and safely treated by targeting the activity of a protein called eIF4E, which plays a key role in regulating the activity of pain-sensing neurons in the peripheral nervous system called nociceptors. These neurons play a crucial role in neuropathic pain. Their development candidate, 4ET1103, is efficacious in multiple animal models of neuropathic pain and has a favorable preclinical safety profile. 4ET1103 functions via a peripheral site of action and does not get into the brain, limiting the potential for CNS side effects. The company has received over $7 million from NIH HEAL (Helping to End Addiction Long-term) funding and has raised $2 million in Series A private financing.